The bidding war over biotechnology company Metsera (MTSR) has intensified, drawing fierce competition from pharmaceutical ...

Tokyo's benchmark Nikkei 225 index has fallen more than 4% and other shares in Asia also sank after a retreat on Wall Street ...

Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain ...

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that purpose ...

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Wall Street fell as tech giants slide; S&P 500 down 1.2%, Nasdaq drops 2%, Palantir and Nvidia lead losses, Metsera rises.